Literature summary for 2.4.2.28 extracted from

Sommer, J.; Itani, D.M.; Homlar, K.C.; Keedy, V.L.; Halpern, J.L.; Holt, G.E.; Schwartz, H.S.; Coffin, C.M.; Kelley, M.J.; Cates, J.M.
Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma (2010), J. Pathol., 220, 608-617.

Search for more literature for 2.4.2.28

Application

Application	Comment	Organism
drug development	loss of MTAP activity in a subset of chordomas suggests that this group of patients may benefit from chemoselective inhibition of the de novo purine synthesis pathway. Purine synthesis inhibitors may be considered for chordoma patients with MTAP-deficient tumours	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
cytoplasm	cytoplasmic MTAP is not detectable in 39% of chordomas	Homo sapiens	5737	-

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
bone cancer cell	MTAP is not detectable in 39% of chordomas	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
methylthioadenosine phosphorylase	-	Homo sapiens
MTAP	-	Homo sapiens

Expression

Organism	Comment	Expression
Homo sapiens	loss of MTAP expression is significantly correlated with loss of CDKN2A	down

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)